Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jan 7, 2016; 22(1): 145-154
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.145
Table 2 Impact of drug resistant mutations in the the hepatitis B virus Pol on the hepatitis B surface antigen
Antiviral drugsResistance mutationsHBsAg correspondingchanges
Lamivudine (LAM2) Tebivudine (LdT2)rtL180MNo change
rtM204VsI195M
rtM204I2sW1961/S/L
Adefovir (AdV) Tenofovir (TDF) LAM2rtA181T2sW1721
rtA181T2sW172L
rtA181V2sL173F
rtN236TAfter end of HBs open reading frame
Entecavir (ETV)rtI169TsF161H/L
rtT184ANo change
rtT184CsL175F + sL176V
rtT184INo change
rtT184GsL176V
rtT184SsL175F
rtT184MsL1761
rt184LsL175F
rtS202CNo change/sS193F
rtS202IsV194F/S
rtS202GNo change/sS193L
rtM250IAfter end of HBs open reading frame
rtM250VAfter end of HBs open reading frame